Issue archived 12/06/2007
Announcement: Public Teleconference with Dr. Michael Lenardo of the National Institute of Allergy & Infectious Diseases to discuss technologies useful in the treatment of autoimmune and allergic disorders
Scientists at the NIH have discovered a method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejections. This method selectively induces apoptosis of disease causing T lymphocytes, while sparing the majority of T-cells. Cell death is achieved by the cyclical administration of disease specific antigens and IL-2.
Further, the NIH scientists have developed compositions and methods for clinical assessment, diagnosis and treatment of Multiple Sclerosis (MS). The compositions are molecules related to the human proteolipid protein (PLP), and the 21.5 kDA fetal isoform of human myelin basic protein (MBP), including nucleic acids and polypeptides. The polypeptides can be used to assay T-cells for responsiveness to MBP and PLP epitopes. They are further useful as therapeutic agents for treating MS by inducing T-cell apoptosis.
Additional details were published in the Federal Register on Friday, October 26, 2007 [72 FR 60865].
Licensing and collaborative research opportunities will also be discussed.
Date and Time: Tuesday, December 11, 2007 at 2:00 PM (EST)
Contact: Mojdeh Bahar (Email: baharm@mail.nih.gov; Phone: 301-435-2950) for details and Call-in instructions.
Archived Issues..
|
